Top

American Journal of Cardiovascular Drugs

Published in:

01-05-2002 | Leading Article

Effects of the Thiazolidinediones on Cardiovascular Risk Factors

Authors: Lucia Gilling, Pitiporn Suwattee, Cyrus DeSouza, Sunil Asnani, Professor Vivian Fonseca

Published in: American Journal of Cardiovascular Drugs | Issue 3/2002

Abstract

Rosiglitazone and pioglitazone are medications from the thiazolidinedione class of compounds currently available for the treatment of type 2 diabetes mellitus. Traditionally used to enhance insulin sensitivity and decrease plasma insulin levels, added applications have emerged beyond those involving glycemic control. Cardiovascular risk factors associated with insulin resistance such as elevated blood pressure, dyslipidemia, abnormal fibrinolysis, and endothelial and vascular dysfunction have been shown to improve after thiazolidinedione treatment. Therapy with rosiglitazone or pioglitazone has been found to modify vascular reactivity and other processes involved in atherosclerosis. There may be differences between the agents in their effects on plasma lipid characteristics and particle size. These agents serve as excellent adjuncts to oral and insulin therapy for patients with type 2 diabetes mellitus and hold promise for the prevention of cardiovascular disease associated with the insulin resistance syndrome. Clinical trials are in progress to determine whether such therapy will lead to a reduction in cardiovascular events.

Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with Macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000 Aug 12; 321(7258): 412–9PubMedCrossRef

Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607PubMedCrossRef

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285(19): 2486–97CrossRef

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12; 352 (9131): 837-53

Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-α in macrophage differentiation and cholesterol uptake. Nat Med 2001 Jan; 7(1): 41–7PubMedCrossRef

Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000 May; 405(6785): 421–4PubMedCrossRef

Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor [gamma] agonists. J Clin Invest 2000 Aug; 106(4): 467–72PubMedCrossRef

Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000 Apr 5; 283(13): 1695–702PubMedCrossRef

Boden G, Chen X, Capulong E, et al. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 2001 Apr; 50(4): 810–6PubMedCrossRef

10.

Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilitation and nitric oxide production. Diabetes 2000 Jul; 49(7): 1231–8PubMedCrossRef

11.

Straus DS, Glass CK. Cyclopentenone Prostaglandins: New insight on biological activities and cellular targets. Med Res Rev 2001; 21(3): 185–210PubMedCrossRef

12.

Scheen AJ, Lefebvre PJ. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999 Sep; 22(9): 1568–77PubMedCrossRef

13.

Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits troglitazone treatment in NIDDM. Diabetes 1997; 46: 433–9PubMedCrossRef

14.

Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193–203PubMedCrossRef

15.

Troglitazone Study Group. The metabolic effects of troglitazone in non-insulin dependent diabetes [abstract]. Diabetes 1997; 46 Suppl. 1: 149A

16.

Prince MJ, Zagar AJ, Robertson KE. Effect of pioglitazone on HDL-C, a cardiovascular risk factor in type 2 diabetes. American Diabetes Association 61st Scientific Sessions; 2001 Jun 22-26; Philadelphia (PA).

17.

Antonucci T, McLain R, Whitcomb R, et al. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997; 20: 188–93PubMedCrossRef

18.

Davidson PC, Sabbah HT, Steed RD, et al. Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone. American Diabetes Association 61st Scientific Sessions; 2001 Jun; 22-26 Jun; Philadelphia (PA).

19.

Brown V. Detection and management of lipid disorders in diabetes. Diabetes Care 1996; Suppl. 1: S96–102

20.

Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24PubMedCrossRef

21.

Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol 1989; 129: 249–59PubMed

22.

Cominacini L, Garbin U, Pastorino AM, et al. Increased susceptibility of LDL-C to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Diabetes Res 1994; 26: 173–84PubMed

23.

Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350–6PubMedCrossRef

24.

de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298–306PubMedCrossRef

25.

Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma. Cell 1998; 93: 229–40PubMedCrossRef

26.

Chinetti G, Levestal S, Bocher V, et al. PPAR-α and PPAR-δ activators induce cholesterol removal from human macrophage goam cells through stimulation of the ABCA1 pathway. Nat Med 2001 Jan; 7(1): 53–8PubMedCrossRef

27.

Tontonoz P, Nagy L, Alvarez JG, et al. PPAR-gamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241–52PubMedCrossRef

28.

Tack CJ, Demacker PN, Smits P, et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796–9PubMedCrossRef

29.

Khan MA, St Peter JV, Neafus KL, et al. A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. American Diabetes Association 61st Scientific Sessions; 2001 Jun 22–26; Philadelphia (PA).

30.

Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952–7PubMedCrossRef

31.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65CrossRef

32.

Supiano MA, Hogikyan RV, Morrow LA, et al. Hypertension and insulin resistance: role of sympathetic nervous system activity. Am J Physiol 1992; 263 (5 Pt 1): E935–42PubMed

33.

Gaboury CL, Simonson DC, Seely EW, et al. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest 1994; 94: 2295–300PubMedCrossRef

34.

Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest 1994; 94: 1172–9PubMedCrossRef

35.

Shimamoto K, Hirata A, Fukuoka M, et al. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertension. Hypertension 1994; 23 Suppl. I: I–29–33

36.

Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316–20PubMedCrossRef

37.

Nolan JJ, Ludvig B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994 Nov; 331: 1188–93PubMedCrossRef

38.

Tack CJ, Ong MK, Lutterman JA, et al. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 1998; 41: 569–76PubMedCrossRef

39.

Morikang E, Benson SC, Kurtz TW, et al. Effect of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997 Apr; 10 (4 Pt 1): 440–6PubMed

40.

Song J, Walsh MF, Sowers JR, et al. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell calcium currents and not endothelial nitric oxide production. Diabetes 1997; 46(4): 659–64PubMedCrossRef

41.

Zhang HY, Reddy SR, Kotchen TA, et al. Antihypertensive effect of pioglitazone is not invariable associated with increased insulin sensitivity. Hypertension 1994 Jul; 24(1): 106–10PubMedCrossRef

42.

Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995; 96: 354–60PubMedCrossRef

43.

Scherbaum W, for the German pioglitazone study group. Pioglitazone reduces blood pressure in patients with type-2-diabetes mellitus. American Diabetes Association 61st Scientific Sessions; 2001 Jun 22–26; Philadelphia (PA)

44.

Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in zucker fatty rats. Diabetes 1999; 48(7): 1448–53PubMedCrossRef

45.

Bakst A, Schwartz S, Fischer JS, et al. Avandia worldwide awareness registry: Improved metabolic control with initiation of rosiglitazone in a diabetes clinic setting. American Diabetes Association 61st Scientific Sessions; 2001 Jun 22–26; Philadelphia, (PA)

46.

Blackman DJ, Morris-Thurgood JA, Atherton JJ, et al. Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans. Circulation 2000 Jan 18; 101(2): 165–70PubMedCrossRef

47.

Cardillo C, Kilcoyne CM, Cannon III RO, et al. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000 Jun; 35(6): 1237–41PubMedCrossRef

48.

Tooke J. The association between insulin resistance and endotheliopathy. Diabetes Obes Metab 1999 May; 1 Suppl. 1: S17–22PubMedCrossRef

49.

Steinberg HO, Bretchel G, Johnson A, et al. Insulin mediated skeletal muscle vasodilatation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1996; 97: 2601–10PubMedCrossRef

50.

Kahn AM, Allen JC, Seidel CL, et al. Insulin inhibits migration of vascular smooth muscle cells with inducible nitric oxide synthase. Hypertension 2000 Jan; 35 (1 Pt 2): 303–6PubMedCrossRef

51.

Kahn NN, Bauman WA, Hatcher VB, et al. Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans. Am J Physiol 1993 Dec; 265 (6 Pt 2): H2160–7PubMed

52.

Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999 Jul 8; 84(1A): J21–4CrossRef

53.

Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420–6PubMedCrossRef

54.

Ohta MY, Nagai Y, Takamura T, et al. Inhibitory effects of troglitazone on TNF-alpha induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells. Diabetes Res Clin Pract 2000 Jun; 48(3): 171–6PubMedCrossRef

55.

Cominacini L, Garbin U, Pasini AF, et al. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhes Commun 1999; 7(3): 223–31PubMedCrossRef

56.

Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000 Aug; 106(4): 523–31PubMedCrossRef

57.

Prigeon RL, Kahn SE, Porte Jr D. Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 1998 Mar 1998; 83(3): 819–23PubMedCrossRef

58.

Yamasaki Y, Kawamori R, Wasada T, et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 glucose clamp study group, Japan. Tohoku J Exp Med 1997 Nov; 183(3): 173–83

59.

Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator—activated receptor-gamma. Diabetes 2001 May; 50(5): 1083–92PubMedCrossRef

60.

Lehmann ED, Riley WA, Clarkson P, et al. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet 1997; 98 Suppl.: I–111A

61.

Avena R, Mitchell ME, Nylen ES, et al. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 1998; 28: 1024–31PubMedCrossRef

62.

Mohanty P, Aljada A, Dandonap P, et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte Chemotactic Protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. American Diabetes Association 61st Scientific Sessions, 2001 Jun 22–26; Philadelphia (PA)

63.

Yashimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 1999 Aug; 145(2): 333–40CrossRef

64.

Murao K, Imachi H, Momoi A, et al. Thiazolidinediones inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 1999 July 2; 454(1-2): 27–30PubMedCrossRef

65.

Vita JA, Frei B, Holbrook M, et al. L-2-Oxathiazolidene-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest 1998 Mar 15; 101(6): 1408–14PubMedCrossRef

66.

Kato K, Satoh H, Endo Y, et al. Thiazolidenediones down regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPAR gamma in endothelial function. Biochem Biophys Res Commun 1999 May 10; 258(2): 431–5PubMedCrossRef

67.

Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab Mar 2001; 86(3): 1306–12CrossRef

68.

Asnao M, Nakajima T, Iwasawa K, et al. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 1999 Oct; 128(3): 673–83CrossRef

69.

Ali SS, Igwe RC, Walsh MF, et al. Troglitazone and vascular reactivity: role of glucose and calcium. Metabolism 1999 Jan; 48(1): 125–30PubMedCrossRef

70.

O’Leary DH, Polak JF, Kronmal RA, et al. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22PubMedCrossRef

71.

Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86(7): 3452–6PubMedCrossRef

72.

Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998 May; 83(5): 1818–20PubMedCrossRef

73.

Jiang C, Ting AT, Seed B. PPARα agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82–6PubMedCrossRef

74.

Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARα: differentiation-dependent peroxisomal proliferator-activated receptor α (PPARα) expression and reduction of MMP-9 activated through PPAR activation in mononuclear macrophages in vitro. Am J Pathol 1998; 152: 17–23CrossRef

75.

Marx N, Schonbeck U, Lazar MA, et al. Peroxisone proliferator-activated receptor-α activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998; 83: 1097–103PubMedCrossRef

76.

Melidonis A, Stefanidis A, Tournis S, et al. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 2000; 23: 160–4PubMedCrossRef

77.

Sobel BE. Coronary artery disease and fibrinolysis: from the blood to the vessel wall. Thromb Haemost 1999; 82 Suppl. 1:8–13PubMed

78.

Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 85: 1563–8

79.

Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998 Jul-Aug; 12(4): 181–6PubMedCrossRef

80.

Kato K, Yamada D, Midorikawa S, et al. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus. Metabolism 2000 May; 49(5): 662–5PubMedCrossRef

81.

Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000 Apr; 49(4): 633–9PubMedCrossRef

82.

Gottschling-Zeller H, Rohrig K, Hauner H. troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia 2000 Mar; 43(3): 377–83PubMedCrossRef

83.

Nordt TK, Peter K, Bode C, et al. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. J Clin Endocrinol Metab 2000; 85: 1563–8PubMedCrossRef

84.

Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993; 16: 621–9PubMedCrossRef

85.

Mattock MB, Morrish NJ, Viberti GC, et al. Prospective study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes 1992; 41: 736–41PubMedCrossRef

86.

Imano E, Kanda T, Nakatani Y, et al. Effect of Troglitazone on Microalbuminuria in Patients with Incipient Diabetic Nephropathy. Diabetes Care 1998 Dec; 12(21): 2135–9CrossRef

87.

Bakris G, Weston WM, Rappaport EB, et al. Rosiglitazone produces Long-term reductions in Urinary Albumin excretion in Type 2 diabetes [abstract]. Diabetologia 1999; 42 Suppl. 1: 230A

88.

Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-γin mesangial cells. Hypertension 2001 Feb; 37 (2 Pt 2): 722–7PubMedCrossRef

89.

Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129: 36–8PubMed

90.

Lenhard MJ, Funk WB. Failure to develop Hepatic Injury from Rosiglitazone in a Patient with a history of Troglitazone-Induce Hepatitis. Diabetes Care 2001 Jan; 24(1): 168–9PubMedCrossRef

91.

Forman LM, Simmons DA, Diamo RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132: 118–21PubMed

92.

Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone. Ann Intern Med 2000; 132: 121–4PubMed

Title: Effects of the Thiazolidinediones on Cardiovascular Risk Factors
Authors: Lucia Gilling
Pitiporn Suwattee
Cyrus DeSouza
Sunil Asnani
Professor Vivian Fonseca
Publication date: 01-05-2002
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 3/2002
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.2165/00129784-200202030-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of the Thiazolidinediones on Cardiovascular Risk Factors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2002

Perspectives of Drug-Eluting Stents

Opinion and Evidence in Cardiovascular Therapeutics

Cardiovascular Risk in Patients with Early Renal Insufficiency

Can Angiotensin Receptor Antagonists Prevent Restenosis After Stent Placement?

Laser Coronary Angioplasty

Naturoceutical Agents in the Management of Cardiovascular Disease